UPDATE 1-FDA staff reviewers cite concerns over Amgen's cancer vaccine data

April 27, 2015 1:42 PM

15 0

April 27 (Reuters) - The U.S. Food and Drug Administration should not consider an accelerated review of Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday, citing concerns over the design and results of a key study.

The review comes two days before a panel of FDA advisers votes on whether the treatment, a cancer-killing virus called talimogene laherparepvec or "T-Vec", should be approved to treat melanoma.

Also read: FDA clears 1st generic film strip of addiction drug Suboxone

Read more

To category page